Obesity Clinical Trial
To test the feasibility and the efficacy of nutritional interventions in the primary prevention of hypertension in individuals predisposed to the development of hypertension; specifically, to test the hypothesis that reduction of weight and/or decreased sodium intake in obese individuals, or decreased sodium intake with or without increased potassium intake (in men and women, regardless of weight) would prevent the elevation of blood pressure and the incidence of hypertension.
BACKGROUND:
The nature of essential hypertension as a mass public health problem throughout the United
States, and internationally as well, is recognized generally. Prevalence estimates exceed l5
percent in most adult populations. Further, the results of the Hypertension Detection and
Follow-up Program (HDFP) demonstrated the efficacy of antihypertensive therapy even at the
90-l05 mmHg level, which comprises 72 percent of the total hypertensive population. The
Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure
recommended treatment of mild hypertension by pharmacologic or non-pharmacologic therapy to
the lowest diastolic pressure consistent with safety and tolerance. The recommendation was
consonant with the goal blood pressure guidelines for those with baseline pressures from
90-99 mmHg. Hence, there appeared to be a growing consensus that reduction of blood pressure
to levels as low as 80 mmHg might be desirable for optimal cardiovascular health. The Joint
National Committee further recommended that, in young patients with uncomplicated mild
hypertension, the benefits from pharmacologic therapy must be weighed against the cost,
inconvenience, and possible side effects. There was, therefore, a growing concern over the
need for pharmacologic management of hypertension and the public health implications of such
a course of action. These recommendations toward intervention in mild hypertension set a
firm basis for the primary prevention of hypertension.
The association between obesity and elevated blood pressure was widely recognized. Among
hypertensive individuals, numerous studies had shown that short term weight reduction by
caloric restriction resulted in a reduction of blood pressure. Results of several reports of
long-term follow-up of weight reduction efforts indicated that long-term control of weight
at levels compatible with the objectives of the HPT was feasible. A number of investigators
had achieved these levels one or more years after treatment despite minimal intervention
efforts during the follow-up period.
There was strong circumstantial evidence relating sodium intake to hypertension. Most
impressive evidence came from the study of the 'low-salt tribes', subsisting on a very low
sodium intake. They failed to develop hypertension, or even gradual rise of blood pressure
with age. Many studies published on the effect of lowering sodium intake on blood pressure
of hypertensive patients had been positive. In one investigation, blood pressure fell
approximately 9 (systolic)/6 (diastolic) mmHg when sodium intake was reduced from
approximately l80 to l00 mEq/day. Reduction of sodium intake to a level of 70-l00 mEq/day
appeared within the capability of most people and maintenance up to a period of two years
had been indicated with minimal follow-up procedures.
The role of potassium intake in the development and treatment of hypertension was less
clear. As noted above, primitive cultures studied epidemiologically had low sodium intakes
associated with low prevalence and incidence of hypertension but these cultures also
consumed higher levels of potassium. It has been suggested that the ratio of sodium to
potassium may be the most important determinant of blood pressure. Hygienic intervention to
increase potassium intake in free-living populations was the least studied of the procedures
used in the HPT. Potassium intakes > l00 mEq could be achieved without the use of dietary
supplements if individuals consumed large quantities of fruits and vegetables. This natural
intake could also be increased by use of potassium-based baking powder and seasonings.
The study was carried out by four clinical and two resource centers (a Coordinating Center
and a Nutrition and Educational Resource Center). It was to be Phase l of a long-term
intervention trial to determine whether development of hypertension could be prevented in a
population at special risk. The initial phase of the study was directed towards testing the
feasibility of the intervention, alternative modes of recruitment, quantification of sodium
and potassium intake, trends in blood pressure, and the pre-testing of various study
procedures.
Each of the four clinical centers recruited 200 or more eligible 25 to 49 year old
individuals (total 841), either identified through any of a number of multiple community
sources, or through an index of hypertensive cases. The clinical investigators aided by
statistical and data processing support from the Data Coordinating Center and intervention
support through a special Nutrition and Education Resources Center, formed the collaborative
group to test the working hypothesis. The study protocol was completed in the fall of 1982.
Recruitment ended September 30, 1983. The three-year follow-up period ended August 1986.
Analysis of the data ended in December 1988.
DESIGN NARRATIVE:
A randomized, non-blind design with three treatment groups (non-obese) or five groups
(obese), including a no-treatment group in each weight stratum. Intervention methods were
dietary only, and included sodium restriction, sodium restriction plus potassium
supplementation (obese and non-obese), weight reduction, and weight reduction plus sodium
restriction (obese only). This was a pilot study with measures of feasibility including
recruitment success, dietary adherence, and blood pressure differences among the treatment
groups.
;
Allocation: Randomized, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |